Hansoh Pharma Receives NMPA Green Light to Launch HS-10541 Clinical Trials for KRAS G12C Solid Tumors

Bulletin Express05-13

Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) announced that its self-developed Class 1 innovative drug, HS-10541 tablets, has secured Clinical Trial Approval from China’s National Medical Products Administration. The authorization permits the company to initiate clinical studies targeting patients with KRAS G12C-mutated advanced solid tumors.

HS-10541 represents a strategic addition to Hansoh Pharma’s oncology pipeline, reinforcing the group’s focus on addressing high-unmet medical needs through internally developed therapies. The approval positions the company to begin patient enrollment and trial site preparation in mainland China.

The board of directors, chaired by Ms. Zhong Huijuan, released the information on 13 May 2026. Executive directors Ms. Sun Yuan and Dr. Lyu Aifeng, together with four independent non-executive directors, endorsed the announcement.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1117801101?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-13 20:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117801101","market":"us","top_or_hot":-1,"title":"Hansoh Pharma Receives NMPA Green Light to Launch HS-10541 Clinical Trials for KRAS G12C Solid Tumors","media":"Bulletin Express","content":"<p>Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) announced that its self-developed Class 1 innovative drug, HS-10541 tablets, has secured Clinical Trial Approval from China’s National Medical Products Administration. The authorization permits the company to initiate clinical studies targeting patients with KRAS G12C-mutated advanced solid tumors.</p>\n<p>HS-10541 represents a strategic addition to Hansoh Pharma’s oncology pipeline, reinforcing the group’s focus on addressing high-unmet medical needs through internally developed therapies. The approval positions the company to begin patient enrollment and trial site preparation in mainland China.</p>\n<p>The board of directors, chaired by Ms. Zhong Huijuan, released the information on 13 May 2026. Executive directors Ms. Sun Yuan and Dr. Lyu Aifeng, together with four independent non-executive directors, endorsed the announcement.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hansoh Pharma Receives NMPA Green Light to Launch HS-10541 Clinical Trials for KRAS G12C Solid Tumors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHansoh Pharma Receives NMPA Green Light to Launch HS-10541 Clinical Trials for KRAS G12C Solid Tumors\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-13 20:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) announced that its self-developed Class 1 innovative drug, HS-10541 tablets, has secured Clinical Trial Approval from China’s National Medical Products Administration. The authorization permits the company to initiate clinical studies targeting patients with KRAS G12C-mutated advanced solid tumors.</p>\n<p>HS-10541 represents a strategic addition to Hansoh Pharma’s oncology pipeline, reinforcing the group’s focus on addressing high-unmet medical needs through internally developed therapies. The approval positions the company to begin patient enrollment and trial site preparation in mainland China.</p>\n<p>The board of directors, chaired by Ms. Zhong Huijuan, released the information on 13 May 2026. Executive directors Ms. Sun Yuan and Dr. Lyu Aifeng, together with four independent non-executive directors, endorsed the announcement.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03692","symbol_name":"翰森制药","start_time":0,"source_url":"","article_id":"1117801101","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117801101","pubTimestamp":1778676172,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) announced that its self-developed Class 1 innovative drug, HS-10541 tablets, has secured Clinical Trial Approval from China’s National...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03692":"翰森制药"},"translate_title":"翰森制药获NMPA批准启动针对KRAS G12C实体瘤的HS-10541临床试验","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1},"content_text":"Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) announced that its self-developed Class 1 innovative drug, HS-10541 tablets, has secured Clinical Trial Approval from China’s National Medical Products Administration. The authorization permits the company to initiate clinical studies targeting patients with KRAS G12C-mutated advanced solid tumors.\nHS-10541 represents a strategic addition to Hansoh Pharma’s oncology pipeline, reinforcing the group’s focus on addressing high-unmet medical needs through internally developed therapies. The approval positions the company to begin patient enrollment and trial site preparation in mainland China.\nThe board of directors, chaired by Ms. Zhong Huijuan, released the information on 13 May 2026. Executive directors Ms. Sun Yuan and Dr. Lyu Aifeng, together with four independent non-executive directors, endorsed the announcement.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1117801101","isCrawlerRequest":true}